Eldecalcitol reduces risk of vertebral fractures in osteoporotic patients .
This report has been verified
by one or more authors of the
original publication.
A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study
Bone. 2011 Oct;49(4):605-12. doi: 10.1016/j.bone.2011.07.011. Epub 2011 Jul 191087 patients were randomized to determine the difference between two vitamin D analogs on the reduction of vertebral fractures in osteoporotic patients. Enrolled patients were allocated to receive eldecalcitol or alfacalcidol once daily, and were followed for 3 years. The results indicated that eldecalcitol reduced the risk of vertebral and wrist fractures, improved lumbar spine and total hip bone mineral density and decrease serum levels of bone turnover markers compared to alfacalcidol, but was associated with increased serum and urinary calcium levels.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
